

Background resources on long-acting injectable cabotegravir for PrEP (CAB PrEP)

AUGUST 2022

[Click here](#) to access the July 28, 2022 WHO Guidelines on long-acting injectable cabotegravir for HIV prevention.

Background on CAB PrEP

Research:

- [Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women \(NEJM 2021\)](#)
- [HPTN 083 Study Results](#) (resource page)
 - [HPTN 083 Preliminary Study Results](#) (webinar)
 - [FAQ](#) (2020)
 - [HPTN 083 FAQ AIDS2020](#)
- [HPTN 084 Study Results](#) (resource page)
 - [HPTN 084 Primary Study Results](#) (video)
 - [FAQ](#) (2020)
 - [Open Label Extension FAQ](#) (2021)
- [Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084](#) (poster)
- [Long Acting Injectable Cabotegravir is Safe and Effective in Preventing HIV Infection in Cisgender Women: Results from HPTN 084 \(HIV R4P 2021\)](#) (video)
- [FDA Approved Apretude Label](#) (2021)

Implementation support materials/tools:

- [A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP](#) (2022 report)
- [Product Introduction/Implementation Project Planning for Next-Generation PrEP](#) (meeting summary)
- [HIV Testing and CAB PrEP Introduction: What are the Implications for HIV prevention scale-up and the HIV response?](#) (AVAC/BioPIC & WHO meeting summary)
- CASPR CAB PrEP (slide decks)
 - [For Advocates](#)
 - [Testing](#)
 - [Product Introduction Basics](#)

- [An Advocate’s Primer on Long-Acting Injectable Cabotegravir for PrEP](#) (technical brief)
- [Ethical issues in long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial 2021](#) (The Lancet 2021)
- [HPTN 083 Community Webinar](#) (2020)
- [HPTN 083: Injectable Cabotegravir vs. Oral Truvada® for Cisgender MSM and Transgender Women](#) (presentation)
- [HPTN 083: The HIV Life Cycle Without Cabotegravir](#) (animation)
- [HPTN 083: The HIV Life Cycle WITH Cabotegravir](#) (animation)
- [Long-Acting Injectable Cabotegravir for PrEP: Understanding Results of HPTN 083 & 084 and key areas for advocacy | AVAC](#) (webinar)
- [MOSAIC PREP Learning Network Kick-off: An Exploration of CAB PrEP](#) (webinar)
 - [Slides](#)

Helpful pages on PrEPWatch.org

- [About Cabotegravir \(CAB-LA\)](#)
- [Evidence and Research for Cabotegravir \(CAB-LA\)](#)

Other helpful links

- [FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention](#)
- [Long-Acting Injectable Cabotegravir](#) (AVAC landing page)
- [The Years Ahead in Biomedical HIV Prevention Research | AVAC](#)